Keros Therapeutics (KROS) Equity Ratio: 2019-2025
Historic Equity Ratio for Keros Therapeutics (KROS) over the last 6 years, with Sep 2025 value amounting to 0.95.
- Keros Therapeutics' Equity Ratio rose 2.98% to 0.95 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.95, marking a year-over-year increase of 2.98%. This contributed to the annual value of 0.93 for FY2024, which is 3.36% up from last year.
- Keros Therapeutics' Equity Ratio amounted to 0.95 in Q3 2025, which was up 1.48% from 0.93 recorded in Q2 2025.
- Keros Therapeutics' Equity Ratio's 5-year high stood at 0.97 during Q2 2021, with a 5-year trough of 0.90 in Q4 2023.
- Its 3-year average for Equity Ratio is 0.92, with a median of 0.93 in 2024.
- Its Equity Ratio has fluctuated over the past 5 years, first skyrocketed by 334.82% in 2021, then declined by 5.08% in 2022.
- Quarterly analysis of 5 years shows Keros Therapeutics' Equity Ratio stood at 0.95 in 2021, then decreased by 5.08% to 0.90 in 2022, then declined by 0.72% to 0.90 in 2023, then grew by 3.36% to 0.93 in 2024, then rose by 2.98% to 0.95 in 2025.
- Its Equity Ratio was 0.95 in Q3 2025, compared to 0.93 in Q2 2025 and 0.93 in Q1 2025.